Navigation Links
The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
Date:5/2/2013

EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United Kingdom), following the approval of its first biologic competitor—another TNF-alpha inhibitor—AbbVie/Eisai's Humira. According to the results of a survey conducted nearly one year after the European approval of Humira for ulcerative colitis, 69 percent of gastroenterologists pointed to Remicade as their most preferred biologic, while 27 percent of respondents indicated Humira.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The TreatmentTrends®: Ulcerative Colitis (EU) report finds that Remicade also leads over Humira in patient share estimates across the major European markets. While the new TNF-alpha inhibitor may not trail far behind Remicade in countries such as the United Kingdom and Germany, gastroenterologists from Italy and France provide estimates half those of Remicade. In addition to the relatively recent approval of Humira, physician perception of Humira's efficacy appears to be a factor limiting uptake as nearly one-third of European gastroenterologists noted its efficacy relative to Remicade as a disadvantage, but less than ten percent stated that its relative efficacy was an advantage. These findings may also explain Remicade's higher patient share co
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
2. Allscripts adopts majority voting policy for directors
3. BD Completes Sale of Majority of Discovery Labware Unit
4. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
5. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
6. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
7. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
10. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
11. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:11/27/2014)... One of the major segments ... for implant dentistry comprises dental implants and abutments ... for dental care is bifurcated into two segments: ... segment is composed of large equipment. , View ... http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental market is ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection of ... player promotion for Dec. 2014. , The CEO of ... April, and this promotion will help to expand our customer ... on our website, she/he can contact us with special need. ... come in the latest designs, and they actually are a ...
(Date:11/27/2014)... Providenciales, Turks and Caicos Islands; BWI (PRWEB) November 28, ... earlier for the Tuscany Resort in the Turks & ... 44 resorts by TripAdvisor in Providenciales, is announcing a ... oceanfront three bedroom villa rentals. And they are ... the resort. , Additionally, The Tuscany, is having ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of ... procedures in place to counter this. However, it doesn’t ... tainted with menstrual blood are taken as seriously. ... sanitary way to handle tampons and menstrual pads while ... Calif. , He then created a prototype of the ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... Market for EMR and PACS to Reach $9.3 Billion by ... to a new market research report series by iData Research ... market research firm, the U.S. market for Electronic Medical Records ... to more than quadruple in value by 2013. , An ...
... is one of the most vital and dynamic sectors of ... which needs to keep pace with the evolving demands of ... , , New analysis from Frost & Sullivan ( ... Company Profiles , finds that the global medical device market ...
... ... HEALTHeCAREERS Network , ... Englewood, CO (Vocus) July 7, 2009 -- The Texas Hospital Association (THA) ... the state,s hospital members to hundreds of career Web sites., , , , ,"HEALTHeCAREERS ...
... ... Recent data from the Food and Drug Administration’s Adverse Event Reporting System ... disorders reported by users of Reglan (or its generic version, metoclopramide) more ... the manufacturers of Reglan and metoclopramide to add a black-box ...
... July 7 , - Former England ... Rob Hicks, Call on Men to Bat Away Embarrassment and Take,Appropriate ... innings of the Ashes commencing this week, celebrity TV,presenter and former ... to think about their health as well as the Ashes Test,Series ...
... PROVIDE IMMEDIATE BENEFIT TO HEART , A ... to patients. Researchers from the Feinstein Institute for ... biomarkers associated with cardiovascular disease (CVD) in "at ... showed that smoking cessation resulted in significant reductions ...
Cached Medicine News:Health News:iData Research Publishes Market Analysis Series on Electronic Medical Records and PACS 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 3Health News:Texas Hospital Association Endorses HEALTHeCAREERS Network 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 3Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 2Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 3Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 5Health News:News briefs from the July issue of CHEST 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: